Stephanie Toepfer

Dr. Stephanie Toepfer

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2025 in eClinicalMedicine
Verified
Journal Article
Open access
RRRiina Rautemaa-Richardson
Riina Rautemaa-Richardson
LTLena Tschiderer
Lena Tschiderer
Alexandre AlanioAlexandre Alanio
Alexandre Alanio
RBRosemary A. Barnes
Rosemary A. Barnes
SCSharon Chen
Sharon Chen
Michaela LacknerMichaela Lackner
Michaela Lackner
This systematic review and meta-analysis aimed to examine the performance of polymerase chain reaction (PCR) assays for diagnosing mucormycosis. A standardised search was conducted from conception to December 3rd 2024 using PubMed, Embase, Global Health, and Cochrane library. Original studies that used PCR-based methods on any human specimen to diagnose mucormycosis were analysed for eligibility. Using a bivariate meta-analysis, the diagnostic performance of PCR was examined against the European Organisation for Research and Treatment of Cancer-Mycoses Study Group Education and Research Consortium 2020 (EORTC-MSGERC) definitions of proven and probable invasive mould disease, which was modified to include all patients at risk of mucormycosis. The study protocol was registered on the PROSPERO database (CRD42023478667). Of 4855 articles, a total of 30 met inclusion criteria, including 5920 PCR reactions on 5147 non-duplicate specimens from 819 cases of proven/probable mucormycosis and 4266 patients who did not meet the EORTC-MSGERC 2020 criteria. According to specimen type, sensitivity of PCR varied (p < 0.001) whereas specificity was similar (p = 0.662). Bronchoalveolar lavage fluid offered the highest sensitivity of 97.5% (95% CI 83.7-99.7%), specificity of 95.8% (95% CI 89.6-98.4%), positive likelihood ratio (LR+) of 23.5, and negative likelihood ratio (LR-) of 0.03. Tissue provided sensitivity of 86.4% (95% CI 78.9-91.5%), specificity of 90.6% (95% CI 78.1-96.3%), LR+ of 9.2, and LR- of 0.15. Blood provided reduced sensitivity of 81.6% (95% CI 70.1-89.4%), specificity of 95.5% (95% CI 87.4-98.5%), DOR of 95, LR+ of 18.3, and LR- of 0.19. Formalin-fixed paraffin-embedded specimens yielded the lowest sensitivity of 73.0% (95% CI 61.0-82.3%), highest specificity of 96.4% (CI 95% 87.5-99.0%), LR+ of 20.2, and LR- of 0.28. The covariates best explaining heterogeneity of the overall analysis were specimen type, study design (cohort versus case-control) and disease prevalence while patient population (COVID-19 versus other) and PCR (conventional versus quantitative) had less impact on heterogeneity. This meta-analysis confirms the high performance of PCR for diagnosing mucormycosis and supports the instatement of PCR detection of free-DNA in blood, BALF and tissue into future updated definitions and diagnostic guidelines for mucormycosis. None.

7 October 2024 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
STStephanie Toepfer
Stephanie Toepfer
MKMikhail V Keniya
Mikhail V Keniya
Michaela LacknerMichaela Lackner
Michaela Lackner
Brian MonkBrian Monk
Brian Monk
Limited antifungal treatment options and drug resistance require innovative approaches to effectively combat fungal infections. Combination therapy is a promising strategy that addresses these pressing issues by concurrently targeting multiple cellular sites. The drug targets usually selected for combination therapy are from different cellular pathways with the goals of increasing treatment options and reducing development of resistance. However, some circumstances can prevent the implementation of combination therapy in clinical practice. These could include the increased risk of adverse effects, drug interactions, and even the promotion of drug resistance. Furthermore, robust clinical evidence supporting the superiority of combination therapy over monotherapy is limited and underscores the need for further research. Despite these challenges, synergies detected with different antifungal classes, such as the azoles and echinocandins, suggest that treatment strategies can be optimized by better understanding the underlying mechanisms. This review provides an overview of multi-targeting combination strategies with a primary focus on Candidozyma auris infections.

26 November 2024 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
PHParham Hosseini
Parham Hosseini
MKMikhail V Keniya
Mikhail V Keniya
Alia SagatovaAlia Sagatova
Alia Sagatova
STStephanie Toepfer
Stephanie Toepfer
Christoph MüllerChristoph Müller
Christoph Müller
Brian MonkBrian Monk
Brian Monk
Aspergillus fumigatus is intrinsically resistant to the widely used antifungal fluconazole, and therapeutic failure can result from acquired resistance to voriconazole, the primary treatment for invasive aspergillosis. The molecular basis of substrate specificity and innate and acquired resistance of A. fumigatus to azole drugs were addressed using crystal structures, molecular models, and expression in Saccharomyces cerevisiae of the sterol 14α-demethylase isoforms AfCYP51A and AfCYP51B targeted by azole drugs, together with their cognate reductase AfCPRA2 and AfERG6 (sterol 24-C-methyltransferase). As predicted by molecular modelling, functional expression of CYP51A and B required eburicol and not lanosterol. A crowded conformationally sensitive region involving the BC-loop, helix I, and the heme makes AfCYP51A T289 primarily responsible for resistance to fluconazole, VT-1161, and the agrochemical difenoconazole. The Y121F T289A combination was required for higher level acquired resistance to fluconazole, VT-1161, difenoconazole, and voriconazole, and confirms posaconazole, isavuconazole and possibly ravuconazole as preferred treatments for target-based azole-resistant aspergillosis due to such a combination of mutations.

7 January 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
Michaela LacknerMichaela Lackner
Michaela Lackner
STStephanie Toepfer
Stephanie Toepfer
MKMikhail V. Keniya
Mikhail V. Keniya
CLCarlos Lax
Carlos Lax
FNFrancisco E. Nicolas
Francisco E. Nicolas
Brian MonkBrian Monk
Brian Monk
The fungal disease mucormycosis, while generally regarded as rare and not transmitted between individuals, has become increasingly prevalent in disaster areas, among the immunocompromised, and in diabetics especially in response to COVID-19. Treatment options are limited. These include debridement of necrotizing tissue followed by complicated multicomponent therapies with amphotericin B and selected azole drugs, usually having poor outcomes. Mucormycetes are intrinsically resistant to the widely used short-tailed azole drugs fluconazole and voriconazole, but susceptible to the long-tailed, though expensive, azole posaconazole. Knowledge of the crystal structure of Saccharomyces cerevisiae sterol 14α-demethylase (Erg11, Cyp51) led to the hypothesis that this pattern of intrinsic azole resistance and susceptibility is due to the Rhizopus arrhizus CYP51-F5 isoform residues F129 and A291, while the CYP51-F1 isoform residues Y127 and V291 confer susceptibility to both short- and long-tailed azole drugs. The heterologous overexpression of individual recombinant R. arrhizus CYP51 isoforms in a S. cerevisiae host, with or without the cognate NADPH-cytochrome P450 reductase (RaCPR), and selective genetic modification of CYP51-F5 have tested this hypothesis. Complementary gene deletion experiments in Rhizopus microsporus confirm that the amino acid residues that align with R. arrhizus CYP51-F5 F129 and A291 determine the resistance or susceptibility pattern of R. arrhizus to short-, medium-, and long-tailed azoles.

23 April 2026 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
ABAngelika Bauer
Angelika Bauer
AMAstrid Mayr
Astrid Mayr
STStephanie Toepfer
Stephanie Toepfer
KSKathrin Spettel
Kathrin Spettel
Birgit WillingerBirgit Willinger
Birgit Willinger
CLCornelia Lass-Flörl
Cornelia Lass-Flörl
Candidozyma auris (C. auris) is an emerging healthcare-associated yeast of major epidemiological concern because of its multidrug resistance and outbreak potential. We report the recovery of a single C. auris isolate from a used face mask collected in May 2025 during a blinded dental medicine quality-control programme assessing microbial contamination in the working environment. To contextualise this finding, we analysed routine diagnostic laboratory data from 2017 to 2025. The isolate underwent whole-genome sequencing for molecular characterisation, including analysis of the ERG11 gene, and antifungal susceptibility testing by EUCAST broth microdilution. In addition, 53,802 patient-related Candida spp. isolates collected between 2017 and 2025 were reviewed retrospectively; species identification had been performed by MALDI-TOF. The environmental isolate belonged to clade III and carried the V125A/F126L substitutions in ERG11, consistent with African clade isolates and associated with intrinsically high fluconazole minimum inhibitory concentrations. No C. auris was detected in routine patient specimens during the study period, whereas Candida albicans remained the predominant species in clinical samples. These findings provide no evidence of ongoing C. auris transmission at the Medical University of Innsbruck, but highlight the need for continued vigilance and robust infection-prevention measures to limit the risk posed by isolated introductions.